In a treatment analysis of gliomas, plumbagin was considered a potential anti-invasive agent that silenced the PI3K/Akt pathway, suggesting that the PI3K/Akt pathway could be used as a therapeutic biomarker [38]. This evidence concerns the gene AKT1 and central nervous system cancer.